Glatiramer acetate (GA)
Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
... to glatiramer acetate (GA) in a prospective way. GA is approved in 57 countries as a 20 mg daily subcutaneous ...to GA is associated with positive treatment outcomes and that the ...
9
Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
... Glatiramer acetate (GA, Copaxone®) is a synthetic amino acid polymer analogue of myelin basic protein and rep- resents one of the first approved therapies for multiple sclerosis (MS) ...(i.e. ...
9
The role of glatiramer acetate in the early treatment of multiple sclerosis
... Glatiramer acetate (GA), a synthetic amino acid co- polymer, is a small molecule that downregulates activated immune cells in some different fashion, but does not apparently affect migration across ...
8
The heritage of glatiramer acetate and its use in multiple sclerosis
... US Glatiramer Acetate phase III study, provided clear evi- dence for the efficacy of GA, demonstrating a significant 29 % reduction favouring GA in annualised relapse rate (ARR) ...of ...
13
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
... of glatiramer acetate (GA) in multiple sclerosis (MS) has been evolving based on recently completed head-to-head studies: REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease); ...
20
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
... One approach to improving efficacy in MS therapy is to identify medications that provide additive or synergistic benefit in combination. Orally administered cholesterol-lowering HMG-CoA reductase inhibitors (known as ...
9
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study
... of glatiramer acetate (GA), an immuno-modulatory and potentially neuro-protective substance which is in clinical use for the treatment of relapsing remitting multiple sclerosis, for the prevention of ...
10
The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation
... weekly glatiramer acetate (GA) on retinal structure and function in diabetic patients who underwent panretinal photocoagulation ...four GA treatments and (2) those who received placebo ...
7
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
... administered for at least 24 weeks under clinical prac- tice conditions. Investigators obtained all the study data from direct review of patients’ medical charts, including information on patients’ clinical follow-up and ...
9
Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)
... Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system in which peripheral blood monocytes play an important role. We have previously reported that patients with chronic progressive MS ...
8
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
... out glatiramer acetate is the best option only in patients with similar health ef- fects, but it could not be the best option in patients with lower health ...
5
Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
... with glatiramer acetate was associated with a reduction in subjective perceptions of fatigue and with the numbers of days taken off work due to ...iramer acetate treatment in ...
6
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
... Health), glatiramer acetate (20 mg/week; Copaxone, Teva), interferon beta-1a (22 ìg/week; Rebif, Serono), and interferon beta-1a (44 ìg/week; ...ramer acetate (box ...
7
Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
... using glatiramer acetate between June 2003 and December 2006 who had enrolled in the patient program run by the pharmaceutical company commercializing the ...to glatiramer acetate treatment in ...
6
Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy
... Backgrond: Muscular dystrophies consist of a number of juvenile and adult forms of complex disorders which generally cause weakness or efficiency defects affecting skeletal muscles or, in some kinds, other types of ...
18
Glatiramer acetate (Copaxone®) induces degenerate, Th2 polarized immune responses in patients with multiple sclerosis
... of glatiramer acetate, a random copolymer of alanine, lysine, glutamic acid, and tyrosine, on antigen-specific T-cell responses in patients with multiple sclerosis ...(MS). Glatiramer acetate ...
11
Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
... Abstract: Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of the first approved drugs for the treatment of relapsing–remitting multiple ...of glatiramer ...
12
Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis
... of GA-induced T cell ...Whereas GA-induced CD4 + T cell responses are comparable in healthy individuals and MS patients, CD8 + T cell responses are significantly lower in untreated MS ...with GA ...
10
Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
... (Copaxone, Teva Pharmaceutical Industries Ltd., Petah Tikva, Israel) in 20 mg doses given daily as a subcutaneous injection. Five of the patients were not treated with any immunomodulatory or immunosuppressive drug prior ...
12
Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)
... adherence or persistence improving programs, it is difficult to determine the best possible combination of such features for any given patient [37]. Zwibel et al. suggested that find- ings in GA-treated RRMS ...
9